SYMTUZA®

DIAMOND STUDY

NEW DATA

SYMTUZA® is the First STR Proven in a Phase 3 Clinical Trial of Patients Rapidly Starting on Treatment1See 48-week results

Reference: 1. Huhn GD, Crofoot G, Ramgopal M, et al. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid initiation model of care for HIV-1 infection: primary analysis of the DIAMOND study. Clin Infect Dis. [published online ahead of print December 27, 2019]. doi:10.1093/cid/ciz1213. 2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/37/whats-new-in-the-guidelines. Updated December 18, 2019. Accessed January 16, 2020.

 

Model portrayals of patients.